Search
Search Results
-
Brain vasculature accumulates tau and is spatially related to tau tangle pathology in Alzheimer’s disease
Insoluble pathogenic proteins accumulate along blood vessels in conditions of cerebral amyloid angiopathy (CAA), exerting a toxic effect on vascular...
-
Serum Tau-A and Tau-C Levels and Their Association with Cognitive Impairment and Dementia Progression in a Memory Clinic Derived Cohort
BackgroundSerum-measured fragments of Tau cleaved by ADAM-10 (Tau-A) and Caspase-3 (Tau-C) have been found linked to change in cognitive function and...
-
Tau seeding and spreading in vivo is supported by both AD-derived fibrillar and oligomeric tau
Insoluble fibrillar tau, the primary constituent of neurofibrillary tangles, has traditionally been thought to be the biologically active, toxic form...
-
A Genetic Validation of the Neurodegeneration Biomarkers Tau-A and Tau-C - A Mendelian Randomization Study
BackgroundDisease modifying treatments for dementia are only just surfacing, and their development is still significantly hindered by the lack of...
-
Toward standardization of tau PET imaging corresponding to various tau PET tracers: a multicenter phantom study
ObjectiveTau positron emission tomography (PET) imaging is a recently developed non-invasive tool that can detect the density and extension of tau...
-
Tau suppresses microtubule-regulated pancreatic insulin secretion
Tau protein is implicated in the pathogenesis of Alzheimer’s disease (AD) and other tauopathies, but its physiological function is in debate. Mostly...
-
Tau: a biomarker of Huntington’s disease
Developing effective treatments for patients with Huntington’s disease (HD)—a neurodegenerative disorder characterized by severe cognitive, motor and...
-
Tau depletion in human neurons mitigates Aβ-driven toxicity
Alzheimer’s disease (AD) is an age-related neurodegenerative condition and the most common type of dementia, characterised by pathological...
-
Phosphorylated tau in the retina correlates with tau pathology in the brain in Alzheimer’s disease and primary tauopathies
The retina is a potential source of biomarkers for the detection of neurodegenerative diseases. Accumulation of phosphorylated tau (p-tau) in the...
-
Tau-targeting therapies for Alzheimer disease: current status and future directions
Alzheimer disease (AD) is the most common cause of dementia in older individuals. AD is characterized pathologically by amyloid-β (Aβ) plaques and...
-
MSUT2 regulates tau spreading via adenosinergic signaling mediated ASAP1 pathway in neurons
Inclusions comprised of microtubule-associated protein tau (tau) are implicated in a group of neurodegenerative diseases, collectively known as...
-
Application of Phosphorylated Tau for Predicting Outcomes Among Sudden Cardiac Arrest Survivors
BackgroundPhosphorylated Tau (p-Tau), an early biomarker of neuronal damage, has emerged as a promising candidate for predicting neurological...
-
CSF p-tau205: a biomarker of tau pathology in Alzheimer’s disease
Post-mortem staging of Alzheimer’s disease (AD) neurofibrillary pathology is commonly performed by immunohistochemistry using AT8 antibody for...
-
A Phase 1 Single-Ascending-Dose Trial in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravenous PNT001, a Novel Mid-domain Tau Antibody Targeting cis-pT231 Tau
BackgroundPNT001 is a humanized full-length IgG4 S228P monoclonal antibody that binds the cis conformation of the phosphorylated Thr231-Pro232 motif...
-
Semorinemab Pharmacokinetics and The Effect on Plasma Total Tau Pharmacodynamics in Clinical Studies
BackgroundSemorinemab is a monoclonal antibody that targets the N-terminal domain of the tau protein that is in clinical development for the...
-
Loss of TMEM106B exacerbates Tau pathology and neurodegeneration in PS19 mice
TMEM106B , a gene encoding a lysosome membrane protein, is tightly associated with brain aging, hypomyelinating leukodystrophy, and multiple...
-
Two-Year Prognostic Utility of Plasma p217+tau across the Alzheimer’s Continuum
BackgroundPlasma p217+tau has shown high concordance with cerebrospinal fluid (CSF) and positron emission tomography (PET) measures of amyloid-β (Aβ)...
-
Longitudinal striatal dopamine transporter binding and cerebrospinal fluid alpha-synuclein, amyloid beta, total tau, and phosphorylated tau in Parkinson’s disease
BackgroundPrevious studies investigated CSF levels of α-synuclein (α-syn), amyloid-β (Aβ1-42), total tau (t-tau), and phosphorylated tau (p-tau) with...
-
Tau pathology is associated with synaptic density and longitudinal synaptic loss in Alzheimer’s disease
The associations of synaptic loss with amyloid-β (Aβ) and tau pathology measured by positron emission tomography (PET) and plasma analysis in...
-
Tau accumulation is associated with dopamine deficiency in vivo in four-repeat tauopathies
PurposeWe hypothesized that severe tau burden in brain regions involved in direct or indirect pathways of the basal ganglia correlate with more...
